Clinical Trial Update: Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR [NA]

View source ↗

Summary

A completed clinical trial comparing bortezomib to rituximab plus plasmapheresis for antibody-mediated rejection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection

Drugs mentioned

• Bortezomib (bortezomib)
• Rituximab (rituximab)

Snippet

Sponsor: Shahid Beheshti University of Medical Sciences | Conditions: Antibody-mediated Rejection | NA | Status: COMPLETED